The Dow Jones Industrial Average is declining Wednesday morning with shares of Amgen and Merck seeing the biggest losses for the price-weighted average. Supported by world-class markets data from ...

Pfizer and AbbVie shares declined more than 4%, Merck dropped almost 4%, and Eli Lilly pulled back over 3% in early trading. Daily Merck & Company, Inc. Dow pharmaceutical components are leading ...

Lusaka [Zambia] / Mumbai (Maharashtra) [India], April 7: Merck Foundation, the philanthropic arm of Merck KGaA Germany marks "World Health Day" 2025 in partnership with Africa's First Ladies who ...

More than 200 members of the United Steelworkers Union Local 10-00086 at Merck & Co. rallied outside Building 53 near Gate 1 at the Upper Gwynedd pharmaceutical giant Wednesday afternoon in support of ...

Merck has shared data from the pivotal 3475A-D77 Phase 3 trial evaluating the subcutaneous administration of pembrolizumab together with berahyaluronidase alfa (subcutaneous pembrolizumab). The study ...

Mer­ck KGaA is spend­ing $85 mil­lion to tap glob­al com­mer­cial­iza­tion rights to pim­i­co­tinib, a can­di­date for non-ma­lig­nant tu­mors that it li­censed from Chi­na’s ...

Merck will partner with Chinese biotech Abbisko Therapeutics to market and sell the bone-tumor treatment pimicotinib globally, expanding its commercialization rights for the drug beyond Asia. The ...

Merck’s new formulation of the mega-blockbuster Keytruda, made in collaboration with Alteogen, could help to keep the drug’s patent cliff at bay. In a push to keep the Keytruda gravy train on the ...

German life sciences and pharma company Merck KGaA (MRK: DE) today revealed it has exercised its option with China’s Abbisko Therapeutics (HKEX: 02256) for commercialization of pimicotinib in the US ...

Mer­ck shared Phase 3 da­ta show­ing that an in­jectable ver­sion of its block­buster can­cer drug Keytru­da is com­pa­ra­ble to the ap­proved … ...

Merck (MRK) released phase III data for an injection form of its blockbuster cancer treatment drug Keytruda and announced the FDA is reviewing the application for approval. The data showed that ...

Merck's stock trades at a low valuation as investors worry about Keytruda's looming patent cliff. The company is looking to a new, subcutaneous formulation, which could help sales remain strong ...